Literature DB >> 12186885

A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.

Nesrina Imami1, Antonio Pires, Gareth Hardy, Jamie Wilson, Brian Gazzard, Frances Gotch.   

Abstract

Previous reports have emphasized the requirements for strong type 1 cell-mediated responses in the control of human immunodeficiency virus type 1 (HIV-1). HIV-1 Gag p24-specific CD4 helper T-lymphocyte (HTL) responses have been shown to inversely correlate with viral burden in HIV-1-infected individuals. In this study, peripheral blood mononuclear cells from 70 individuals with chronic progressive HIV-1 infection (clinical progressors), 10 clinical nonprogressors, and 3 immunologically discordant progressors were assessed for HTL proliferation and type 1/type 2 cytokine production. Clinical progressors lacked functional HIV-1-specific HTLs with proliferative and cytokine-producing capacity. Clinical nonprogressors were found to respond to a wide range of HIV-1 antigens from different clades, producing both type 1 and type 2 cytokines. Immunologically discordant progressors responded strongly to clade B Gag p24 with a type 1 cytokine profile but not to other antigens. Thus, in contrast to clinical nonprogressors, neither progressors nor immunologically discordant progressors secreted interleukin-4 (IL-4) in response to HIV-1 antigens. Both clinical nonprogressors and immunologically discordant progressors responded broadly to B clade Gag p24-overlapping peptides. However, IL-4 production in the nonprogressors was restricted to a limited number of p24 peptides. No HIV-1-specific T-cell responses were seen in 20 seronegative controls. Additionally, we observed a rapid type 1 to type 2 shift in the response of one immunologically discordant progressor upon onset of clinical symptoms. These results suggest that a balanced type 1/type 2 profile correlates with successful long-term control of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186885      PMCID: PMC136425          DOI: 10.1128/jvi.76.18.9011-9023.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Developmental and maturational changes in human blood lymphocyte subpopulations.

Authors:  I Hannet; F Erkeller-Yuksel; P Lydyard; V Deneys; M DeBruyère
Journal:  Immunol Today       Date:  1992-06

2.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition.

Authors:  H C Lane; J M Depper; W C Greene; G Whalen; T A Waldmann; A S Fauci
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

3.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 4.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Authors:  T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

6.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.

Authors:  B Wahren; L Morfeldt-Månsson; G Biberfeld; L Moberg; A Sönnerborg; P Ljungman; A Werner; R Kurth; R Gallo; D Bolognesi
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  A sensitive and specific bioassay for the detection of human interleukin-10.

Authors:  J F Schlaak; E Schmitt; C Hüls; K H Meyer zum Büschenfelde; B Fleischer
Journal:  J Immunol Methods       Date:  1994-01-12       Impact factor: 2.303

8.  Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.

Authors:  M Battegay; D Moskophidis; A Rahemtulla; H Hengartner; T W Mak; R M Zinkernagel
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

Authors:  J A Berzofsky; A Bensussan; K B Cease; J F Bourge; R Cheynier; Z Lurhuma; J J Salaün; R C Gallo; G M Shearer; D Zagury
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

10.  Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D C Bernstein; D L Mann; G M Shearer; J A Berzofsky
Journal:  Nature       Date:  1989-06-01       Impact factor: 49.962

View more
  35 in total

Review 1.  Studies of HIV-associated immune responses in lymphoid compartments.

Authors:  Susanna Grundström; Jan Andersson
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

2.  Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness.

Authors:  G A D Hardy; N Imami; A K Sullivan; A Pires; C T Burton; M R Nelson; B G Gazzard; F M Gotch
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

3.  Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.

Authors:  Darrilyn G Fraser; Robert H Mealey; Travis C McGuire
Journal:  Immunogenetics       Date:  2003-08-27       Impact factor: 2.846

4.  Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function.

Authors:  C T Burton; S J Westrop; I Eccles-James; A Boasso; M R Nelson; M Bower; N Imami
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

5.  Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.

Authors:  S B Justin Wong; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  HIV-induced changes in T cell signaling pathways.

Authors:  Marc Schweneker; David Favre; Jeffrey N Martin; Steven G Deeks; Joseph M McCune
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

7.  HIV vaccines: can CD4+ T cells be of help?

Authors:  Eva Van Braeckel; Geert Leroux-Roels
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

8.  Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape.

Authors:  Susanne Beckebaum; Vito R Cicinnati; Xia Zhang; Stanislav Ferencik; Andrea Frilling; Hans Grosse-Wilde; Christoph Erich Broelsch; Guido Gerken
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

9.  CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects.

Authors:  M J Boaz; A Waters; S Murad; P J Easterbrook; E D'Sousa; C van Wheeley; A Vyakarnam
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

10.  Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.

Authors:  S Lee; C-A Almeida; M A H French; P Price
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.